Zobrazeno 1 - 10
of 300
pro vyhledávání: '"M Farach"'
Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer
Autor:
Kevin T. Tran, Neil C. Chevli, Jay A. Messer, Waqar Haque, Andrew M. Farach, Raj Satkunasivam, Jun Zhang, Jorge Darcourt, Simon S. Lo, Shankar Siva, Edward B. Butler, Bin S. Teh
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 39, Iss , Pp 100592- (2023)
Purpose /Objectives Materials/Methods: The National Cancer Database (NCDB) was queried (2004–2017) for patients with RCC who did not have surgical resection but received definitive SBRT. Kaplan-Meier analysis with log-rank test was used to evaluate
Externí odkaz:
https://doaj.org/article/de804912361c469fa0701d418de39f89
Autor:
Neil Chevli, MD, Stephen B. Chiang, MD, Andrew M. Farach, MD, Waqar Haque, MD, Raj Satkunasivam, MD, Eric H. Bernicker, MD, Ramiro Pino, PhD, E. Brian Butler, MD, Bin S. Teh, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 6, Pp 100719- (2021)
Purpose: Stereotactic body radiation therapy (SBRT) treatment planning for renal cell carcinoma requires accurate delineation of tumor from normal tissue due to the radiosensitivity of normal renal cortical tissue. Tc-99m dimercapto succinic acid (DM
Externí odkaz:
https://doaj.org/article/afc74d8b8bef446a928ee042c511b219
Autor:
Neil Chevli, MD, Andrew Hunt, MD, Waqar Haque, MD, Andrew M. Farach, MD, Jay A. Messer, MD, Suporn Sukpraprut-Braaten, PhD, Eric H. Bernicker, MD, Jun Zhang, MD, E. Brian Butler, MD, Bin S. Teh, MD
Publikováno v:
Advances in Radiation Oncology, Vol 6, Iss 6, Pp 100783- (2021)
Purpose: Patients with small cell lung cancer (SCLC) who have brain metastases require whole-brain radiation therapy (WBRT). When there is no emergent indication for WBRT, patients may receive systemic therapy first and WBRT afterward. In scenarios w
Externí odkaz:
https://doaj.org/article/23b77eca786246599871a488f00203c1
Autor:
Neil, Chevli, Waqar, Haque, Kevin T, Tran, Andrew M, Farach, Mary R, Schwartz, Sandra S, Hatch, E Brian, Butler, Bin S, Teh
Publikováno v:
Practical Radiation Oncology. 13:e230-e238
The 21-gene RT-PCR recurrence score (RS) is performed in patients with hormone receptor-positive (ER+, PR+), human epidermal growth factor receptor 2 (HER2)-negative, N0 breast cancer to determine which patients will likely benefit from chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9d97ea666db0b1309ebf0515335fa15
https://doi.org/10.1016/j.prro.2022.08.004
https://doi.org/10.1016/j.prro.2022.08.004
Publikováno v:
Current Surgery Reports. 11:30-38
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45fe07cdebb0436f742a80f07af67eeb
https://doi.org/10.1007/s40137-022-00342-9
https://doi.org/10.1007/s40137-022-00342-9
Autor:
Neil, Chevli, Waqar, Haque, Kevin T, Tran, Andrew M, Farach, Mary R, Schwartz, Sandra S, Hatch, E Brian, Butler, Bin S, Teh
Publikováno v:
Radiotherapy and Oncology. 174:37-43
Based on the results of the Cancer and Leukemia Group B (CALGB) 9343 trial, patients age ≥70 with T1N0 hormone receptor positive (ER/PR+), human epidermal growth factor receptor-2 negative (HER2-) breast cancer who are treated with breast conservin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aaacbf58d838aeaab25a146a618dfa66
https://doi.org/10.1016/j.radonc.2022.06.013
https://doi.org/10.1016/j.radonc.2022.06.013
Autor:
Jenny C. Chang, Eric H. Bernicker, Shu-hsia Chen, E. Brian Butler, Zhuyong Mei, Jaime A. Mejia, Joe Ensor, Joseph D. Butner, Thi Truc Anh Nguyen, Xiaoxian Li, Sindhu Nair, Susan L. Haley, Mary R. Schwartz, Nakul Gupta, Mark A. Sultenfuss, Sunil Mathur, Carlo Guerrero, Andrew M. Farach, Bin S. Teh, Tejal Patel, Jorge Darcourt, Polly Niravath, Licheng Zhang, Yitian Xu, Kai Sun
Purpose:A Phase 2 trial of stereotactic radiotherapy and in situ cytotoxic virus therapy in patients with metastatic triple-negative breast cancer (mTNBC) followed by pembrolizumab (STOMP) was designed to evaluate dual approach of enhancing single-ag
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7b23d06b2ed3c95b611b4612ed00e9f0
https://doi.org/10.1158/1078-0432.c.6533004
https://doi.org/10.1158/1078-0432.c.6533004
Autor:
Jenny C. Chang, Eric H. Bernicker, Shu-hsia Chen, E. Brian Butler, Zhuyong Mei, Jaime A. Mejia, Joe Ensor, Joseph D. Butner, Thi Truc Anh Nguyen, Xiaoxian Li, Sindhu Nair, Susan L. Haley, Mary R. Schwartz, Nakul Gupta, Mark A. Sultenfuss, Sunil Mathur, Carlo Guerrero, Andrew M. Farach, Bin S. Teh, Tejal Patel, Jorge Darcourt, Polly Niravath, Licheng Zhang, Yitian Xu, Kai Sun
Supplementary Table from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::469d5b69a454d3f240f7e88f57bafe39
https://doi.org/10.1158/1078-0432.22489656
https://doi.org/10.1158/1078-0432.22489656
Autor:
Jenny C. Chang, Eric H. Bernicker, Shu-hsia Chen, E. Brian Butler, Zhuyong Mei, Jaime A. Mejia, Joe Ensor, Joseph D. Butner, Thi Truc Anh Nguyen, Xiaoxian Li, Sindhu Nair, Susan L. Haley, Mary R. Schwartz, Nakul Gupta, Mark A. Sultenfuss, Sunil Mathur, Carlo Guerrero, Andrew M. Farach, Bin S. Teh, Tejal Patel, Jorge Darcourt, Polly Niravath, Licheng Zhang, Yitian Xu, Kai Sun
Supplementary Figure from A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b12c83a0c92317811b616c26e0a3107
https://doi.org/10.1158/1078-0432.22489665
https://doi.org/10.1158/1078-0432.22489665
Autor:
Neil Chevli, Kaidi Wang, Waqar Haque, Mary R. Schwartz, Julie Nangia, Jennifer Sasaki, Andrew M. Farach, Sandra S. Hatch, E. Brian Butler, Bin S. Teh
Publikováno v:
Cancer Research. 82:P3-19
Purpose/Objectives Mucinous carcinoma (MC) of the breast is an uncommon variant of breast cancer which has a favorable prognosis. Current guidelines for ER/PR-positive, HER2-negative pure-MC state that endocrine therapy (ET) is only required for tumo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::05e3ac7616621228baf8fe589a33f798
https://doi.org/10.1158/1538-7445.sabcs21-p3-19-15
https://doi.org/10.1158/1538-7445.sabcs21-p3-19-15